Results of the Combined General Meeting of 28 June 2024 Lyon (France) and Cambridge (MA, US), 28 June 2024 - 5.45 pm CEST - PHAXIAM...
PHAXIAM Therapeutics annonce le succès de son augmentation de capital avec maintien du droit préférentiel de souscription de 7,8 M€ Lyon...
Lancement d'une augmentation de capital avec maintien du DPS d’un montant d’environ 10 M€, susceptible d’être porté à environ 11,5 M€ en...
PHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024 Lyon (France) and Cambridge...
Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2024 Article 223-16 of...
PHAXIAM Therapeutics fait le point sur ses activités et publie l’information financière du premier trimestre 2024 PHAXIAM Therapeutics fait...
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024 Article 223-16 of...
PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by...
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 mars 2024 Information...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads